MX2022001356A - Microparticulas similares a pelotas de golf para uso en el tratamiento y prevencion de enfermedades pulmonares. - Google Patents

Microparticulas similares a pelotas de golf para uso en el tratamiento y prevencion de enfermedades pulmonares.

Info

Publication number
MX2022001356A
MX2022001356A MX2022001356A MX2022001356A MX2022001356A MX 2022001356 A MX2022001356 A MX 2022001356A MX 2022001356 A MX2022001356 A MX 2022001356A MX 2022001356 A MX2022001356 A MX 2022001356A MX 2022001356 A MX2022001356 A MX 2022001356A
Authority
MX
Mexico
Prior art keywords
prevention
treatment
golf ball
microparticles
pulmonary diseases
Prior art date
Application number
MX2022001356A
Other languages
English (en)
Inventor
Brigitte Evrard
Didier Cataldo
Paul Maes
William Bigazzi
Original Assignee
Aquilon Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aquilon Pharmaceuticals filed Critical Aquilon Pharmaceuticals
Publication of MX2022001356A publication Critical patent/MX2022001356A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a unas micropartículas similares a pelotas de golf obtenidas por atomización de nanosuspensiones de nanopartículas o soluciones para inhaladores de polvo seco para uso en el tratamiento y prevención de enfermedades pulmonares.
MX2022001356A 2019-09-10 2020-09-10 Microparticulas similares a pelotas de golf para uso en el tratamiento y prevencion de enfermedades pulmonares. MX2022001356A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
BE20195603A BE1027612B1 (fr) 2019-09-10 2019-09-10 Microparticules en forme de balle de golf pour une utilisation dans le traitement et la prevention de maladies pulmonaires
PCT/EP2020/075416 WO2021048322A1 (en) 2019-09-10 2020-09-10 Golf ball-like microparticles for use in the treatment and prevention of pulmonary diseases

Publications (1)

Publication Number Publication Date
MX2022001356A true MX2022001356A (es) 2022-07-19

Family

ID=68426040

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022001356A MX2022001356A (es) 2019-09-10 2020-09-10 Microparticulas similares a pelotas de golf para uso en el tratamiento y prevencion de enfermedades pulmonares.

Country Status (10)

Country Link
US (1) US20230218515A1 (es)
EP (2) EP4003320B1 (es)
KR (1) KR20220050951A (es)
CN (1) CN114364374A (es)
BE (1) BE1027612B1 (es)
BR (1) BR112022003696A2 (es)
CA (1) CA3150551C (es)
ES (1) ES2942901T3 (es)
MX (1) MX2022001356A (es)
WO (1) WO2021048322A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102665978B1 (ko) * 2021-11-22 2024-05-13 충북대학교 산학협력단 딤플 구조의 표면을 가진 마이크로 입자의 제조 방법
WO2023118014A1 (en) 2021-12-20 2023-06-29 Aquilon Pharmaceuticals Inhalable compositions comprising a complex of hpbcd and budesonide or ciclesonide for the treatment or prevention of a respiratory viral disease or lipopolysaccharide-induced inflammation, in particular lipopolysaccharide-induced inflammation associated with a respiratory viral disease
BE1029585B1 (fr) * 2021-12-20 2023-02-03 Aquilon Pharmaceuticals Compositions inhalables comprenant un complexe de hpbcd et de budesonide ou ciclesonide pour le traitement ou la prevention d'une maladie virale respiratoire
BE1030002B1 (fr) 2021-12-29 2023-09-01 Aquilon Pharmaceuticals Compositions inhalables comprenant un complexe de hpbcd et de budesonide ou ciclesonide pour le traitement ou la prevention d'une maladie virale respiratoire

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006200277B2 (en) 1997-09-29 2008-04-10 Novartis Ag Perforated microparticles and methods of use
FI20002215A0 (fi) * 2000-10-06 2000-10-06 Orion Yhtymae Oyj Yhdistelmäpartikkelit
GB0228826D0 (en) 2002-12-11 2003-01-15 Okpala Joseph Hair technology in creating particles with improved delivery capabilities
EP1655034A1 (en) 2004-10-10 2006-05-10 Université de Liège Use of cyclodextrin for treatment and prevention of bronchial inflammatory diseases.
AU2006269961B2 (en) 2005-07-15 2012-07-19 Map Pharmaceuticals, Inc. Multiple active pharmaceutical ingredients combined in discrete inhalation particles and formulations thereof
WO2007086039A1 (en) * 2006-01-27 2007-08-02 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth, Near Dublin A method of producing porous microparticles
EP2785326A2 (en) 2011-11-29 2014-10-08 The University of North Carolina at Chapel Hill Geometrically engineered particles and methods for modulating macrophage or immune responses
EP2981247B1 (en) * 2013-04-01 2023-06-07 Pulmatrix Operating Company, Inc. Tiotropium dry powders
EP2923702A1 (en) 2014-03-28 2015-09-30 Universite De Liege Composition of cyclodextrin with budesonide derivatives for treatment and prevention of pulmonary inflammatory disease
CN106924193A (zh) 2017-03-20 2017-07-07 谭淞文 一种高孔隙率干粉吸入剂载体及其超饱和合成法和应用

Also Published As

Publication number Publication date
WO2021048322A1 (en) 2021-03-18
BR112022003696A2 (pt) 2022-05-24
EP4003320B1 (en) 2023-03-08
ES2942901T3 (es) 2023-06-07
CN114364374A (zh) 2022-04-15
EP4003320A1 (en) 2022-06-01
KR20220050951A (ko) 2022-04-25
BE1027612A1 (fr) 2021-04-27
CA3150551A1 (en) 2021-03-18
CA3150551C (en) 2023-10-10
US20230218515A1 (en) 2023-07-13
EP4190321A1 (en) 2023-06-07
BE1027612B1 (fr) 2021-05-03

Similar Documents

Publication Publication Date Title
MX2022001356A (es) Microparticulas similares a pelotas de golf para uso en el tratamiento y prevencion de enfermedades pulmonares.
CY1120605T1 (el) Παρασκευασμα ξηρης σκονης που περιλαμβανει εναν αναστολεα φωσφοδιεστερασης
MY196072A (en) Liquid Inhalation Formulation Comprising RPL554
PH12018502530A1 (en) Substituted indazoles useful for treatment and prevention of allergic and/or inflammatory diseases in animals
MX354829B (es) Formulaciones de polvo seco y metodos para el tratamiento de enfermedades pulmonares.
TN2012000428A1 (en) Bisaryl-bonded aryltriazolones and use thereof
TN2012000566A1 (en) Dry powder formulation comprising an antimuscarinic drug
GEP20186865B (en) Dry powder inhaler and inhalation actuated mechanism thereof
WO2014078575A3 (en) Novel orally bioavailable breathing control modulating compounds, and methods of using same
WO2014141210A3 (en) Multifunctional immature dental pulp stem cells and therapeutic applications
ZA202104378B (en) Dry powder inhalation formulation and its use for the therapeutic treatment of lungs
PL3307293T3 (pl) Preparaty do leczenia zaburzeń jamy ustnej, gardła i dróg oddechowych
PH12016500608A1 (en) Cyclic thienouracil-carboxamides and use thereof
PH12019501785A1 (en) Intranasal composition comprising betahistine
WO2016032148A3 (ko) 서방출 및 생체 적합성이 개선된 카토제닌-키토산 복합체 입자 및 이의 이용
EA202091618A1 (ru) Композиция кетамина в виде сухого порошка для применения при лечении депрессии ингаляционным путем
RU2016133264A (ru) Ускоритель продуцирования катехоламина и терапевтическое и профилактическое средство и терапевтическая и профилактическая пищевая композиция для заболеваний, обусловленных недостаточностью катехоламина
WO2013181217A3 (en) Novel compounds and compositions for treatment of breathing control disorders or diseases
SG10201803748VA (en) Methods and treatment for certain demyelination and dysmyelination-based disorders and/or promoting remyelination
MX2019013570A (es) Particulas portadoras novedosas para formulaciones de polvo seco para inhalacion.
MX2017004633A (es) Formulaciones que contienen tiotropio, aminoacidos y acidos, y metodos de estas.
EP3842029A4 (en) NANOSTRUCTURED NANOPARTICLES COMPRISING ONE OR MORE ACTIVE INGREDIENTS FOR THE TREATMENT OF DISEASES PRODUCED BY TRYPANOSOMES AND FOR THE TREATING OF TUMORS OF NEURAL ORIGIN, COMPOSITIONS COMPRISING THESE NANOSTRUCTURED NANOPARTICLES, METHOD FOR THE PREPARATION AND THERAPEUTIC USE THEREOF
MX2019001701A (es) Composicion farmaceutica de dosis fija que comprende mometasona y azelastina.
EP3685831A4 (en) USE OF FERRIC CITRATE IN THE PREVENTION AND / OR TREATMENT OF FERRIPRIVE ANEMIA IN A PATIENT WITH HYPERMENORRHEA AND / OR A PATIENT WITH A GYNECOLOGICAL DISEASE ASSOCIATED WITH HYPERMENORRHEA
TN2013000015A1 (en) Dry powder formulation comprising a phosphodiesterase inhibitor